MetaCap

Alkermes (ALKS) vs Madrigal Pharmaceuticals (MDGL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Alkermes (ALKS) has outperformed Madrigal Pharmaceuticals (MDGL) over the past year, gaining 57.1% versus a loss of 30.8%. Over five years, MDGL leads with a +362.0% price change compared with +100.0% for ALKS. Madrigal Pharmaceuticals is the larger company by market cap ($8.81 billion vs $7.55 billion), about 1.2 times the size.

On valuation, Alkermes trades at a lower forward P/E (33.2x vs 36.5x for Madrigal Pharmaceuticals). Alkermes converts more of its revenue into profit, with a net margin of 16.4% versus -30.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALKS+57.08%MDGL-30.82%
+99%+31%-37%
Nov 21, 20251 yearNov 20, 2026
ALKS+93.37%MDGL+360.07%
+660%+298%-64%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALKS versus MDGL key metrics
MetricALKSMDGL
Share price$44.94$379.10
Market cap$7.55B$8.81B
1-day change-2.69%-4.45%
YTD return+60.61%-34.90%
1-year return+57.08%-30.82%
5-year return+100.00%+361.98%
Forward P/E33.2136.52
EPS (TTM)$-0.01$-5.85
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.48B$958.40M
Revenue growth (YoY)-5.25%+432.05%
Net income (latest FY)$241.66M$-288.28M
Gross margin86.69%—
Operating margin17.21%-31.31%
Net margin16.37%-30.08%
52-week high$55.67$615.00
52-week low$27.00$353.54
Distance from 52-week high-19.27%-38.36%
Analyst consensusbuystrong_buy
Avg. price target upside+28.48%+81.69%
Average volume1.90M370.07K
Shares outstanding168.04M23.23M
Employees2,050915
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ALKS has outperformed MDGL by 87.9 percentage points over the past year.
  • Alkermes is more profitable, keeping 16.4 cents of every revenue dollar as net income versus -30.1 cents for Madrigal Pharmaceuticals.
  • Madrigal Pharmaceuticals grew revenue faster in its latest fiscal year (+432.05% vs -5.25%).

About Alkermes

ALKS stock →

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 2,050 employees

About Madrigal Pharmaceuticals

MDGL stock →

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH.

Health Care · Biotechnology: Pharmaceutical Preparations · 915 employees

ALKS vs MDGL FAQ

Which is bigger, Alkermes or Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals (MDGL) is larger, with a market capitalization of $8.81B compared with $7.55B for Alkermes (ALKS).

Which stock has performed better over the past year, ALKS or MDGL?

ALKS returned +57.08% over the past 12 months, compared with -30.82% for MDGL (price return, excluding dividends). Past performance does not predict future results.

Are Alkermes and Madrigal Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons